Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > The position of PMX within Vantive

<< Previous

Bullboard Posts

Next >>

Comment by BlueJays9293on Aug 28, 2024 10:57pm

180 Views

Post# 36200565

RE:RE:RE:The position of PMX within Vantive

There is no Oxiris approval just on her own.

Oxiris is a piggybacker.

She'll do a decent job of getting rid of residual endotoxin as the patient recovers from double barrel PMX,

but Oxiris will also scoop up some Cytokine's and antibiotics, that weren't the bad actors that the researchers thought they were,

in fact they might have been needed at that specific moment.

<< Previous

Bullboard Posts

Next >>

Three business reasons companies need to recycle e-waste